Brief: Genprex Receives U.S. FDA Fast Track Designation For Small Cell Lung Cancer Treatment

Genprex

28/06/2023 13:41

June 28 (Reuters) - Genprex Inc  GNPX.O :
    * GENPREX RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR
REQORSA®
IMMUNOGENE THERAPY IN COMBINATION WITH TECENTRIQ® FOR THE
TREATMENT OF SMALL CELL LUNG CANCER
    * GENPREX INC - IN Q3 OF 2023, EXPECTS TO ENROLL FIRST
PATIENT IN
ITS ACCLAIM-3 CLINICAL TRIAL

Source text for Eikon:  ID:nPn7DLdBJa 
Further company coverage:  GNPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))